251
|
|
252
|
Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation—a Balance of Risks and Benefits. Cardiovasc Drugs Ther 2008; 22:419-25. [DOI: 10.1007/s10557-008-6122-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2008] [Accepted: 06/16/2008] [Indexed: 10/21/2022]
|
253
|
Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA, Mack MJ. Minimally Invasive Pulmonary Vein Isolation and Partial Autonomic Denervation for Surgical Treatment of Atrial Fibrillation. Ann Thorac Surg 2008; 86:35-8; discussion 39. [DOI: 10.1016/j.athoracsur.2008.03.071] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2007] [Revised: 03/26/2008] [Accepted: 03/28/2008] [Indexed: 10/21/2022]
|
254
|
Melduni RM, Malouf JF, Chandrasekaran K, Bruce CJ, White RD, Law KK, Al Atawi FO, Somers VK, Gersh BJ, Hodge DO, Friedman PA, Seward JB, Ammash NM. New Insights Into the Predictors of Left Atrial Stunning After Successful Direct-Current Cardioversion of Atrial Fibrillation and Flutter. J Am Soc Echocardiogr 2008; 21:848-54. [DOI: 10.1016/j.echo.2007.12.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2007] [Indexed: 01/01/2023]
|
255
|
Israel CW. Effect of statins in 'upstream therapy' of atrial fibrillation: better reliability with implantable cardiac monitors. Eur Heart J 2008; 29:1798-9. [PMID: 18567670 DOI: 10.1093/eurheartj/ehn274] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
256
|
Symptoms Versus Objective Rhythm Monitoring in Patients with Paroxysmal Atrial Fibrillation Undergoing Pulmonary Vein Isolation. Eur J Cardiovasc Nurs 2008; 7:147-51. [DOI: 10.1016/j.ejcnurse.2007.08.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Revised: 08/22/2007] [Accepted: 08/28/2007] [Indexed: 11/22/2022]
|
257
|
Janko S, Dorwarth U, Hoffmann E. Pharmacotherapy of atrial fibrillation: an old option with new possibilities. Expert Opin Pharmacother 2008; 9:913-25. [PMID: 18377335 DOI: 10.1517/14656566.9.6.913] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Atrial fibrillation is the most common sustained arrhythmia observed worldwide. Despite modern ablative treatment options, pharmacotherapy remains the first-line therapy in patients with atrial fibrillation. OBJECTIVE Based on recently published guidelines for the management of atrial fibrillation, the present paper reviews the current and emerging concepts of pharmacotherapy in atrial fibrillation. METHODS A MEDLINE search was conducted using the keyword 'atrial fibrillation' and 'drug therapy'. The reviewed literature included clinical trials and published reviews as well as clinical guidelines. RESULTS The mainstay of atrial fibrillation therapy is the prevention of thromboembolic events. With growing knowledge of the pathophysiology of atrial fibrillation new drug targets have been identified that promise improved outcomes in atrial fibrillation management and this will allow individual drug treatment in the near future.
Collapse
Affiliation(s)
- Sabine Janko
- Heart Center Munich-Bogenhausen, Department of Cardiology and Intensive Care Unit, Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Strasse 77, 89125 Munich, Germany
| | | | | |
Collapse
|
258
|
Abstract
Atrial fibrillation (AF) is an epidemic, affecting 1% to 1.5% of the population in the developed world. Projected data from the population-based studies suggest that the prevalence of AF will grow at least 3-fold by 2050. The health and economic burden imposed by AF and AF-related morbidity is enormous. Atrial fibrillation has a multiplicity of causes ranging from genetic to degenerative, but hypertension and heart failure are the commonest and epidemiologically most prevalent conditions associated with AF as both have been shown to create an arrhythmogenic substrate. Several theories emerged regarding the mechanism of AF, which can be combined into two groups: the single focus hypothesis and the multiple sources hypothesis. Several lines of evidence point to the relevance of both hypotheses to the mechanism of AF, probably with a different degree of involvement depending on the variety of AF (paroxysmal or persistent). Sustained AF alters electrophysiological and structural properties of the atrial myocardium such that the atria become more susceptible to the initiation and maintenance of the arrhythmia, a process known as atrial remodeling. Angiotensin II has been recognized as a key element in atrial remodeling in association with AF opening the possibility of exploitation of "upstream" therapies to prevent or delay atrial remodeling. The clinical significance of AF lies predominantly in a 5-fold increased risk of stroke. The limitations of warfarin prompted the development of new antithrombotic drugs, which include anticoagulants, such as direct oral thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban). Novel mechanical approaches for the prevention of cardioembolic stroke have recently been evaluated: percutaneous left atrial appendage occluders, minimally invasive surgical isolation of the left atrial appendage, and implantation of carotid filtering devices.
Collapse
Affiliation(s)
- Irina Savelieva
- St George's University of London, Cranmer Terrace, London, U.K
| | | |
Collapse
|
259
|
Abstract
The risk is negligible, and does not offset the benefits of reducing fractures
Collapse
|
260
|
Sarkar S, Ritscher D, Mehra R. A Detector for a Chronic Implantable Atrial Tachyarrhythmia Monitor. IEEE Trans Biomed Eng 2008; 55:1219-24. [PMID: 18334416 DOI: 10.1109/tbme.2007.903707] [Citation(s) in RCA: 149] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Shantanu Sarkar
- Medtronic, Inc., 8200 Coral Sea Street NE, MVN41, Moundsview, MN 55112 USA.
| | | | | |
Collapse
|
261
|
Abstract
It is well recognized that during atrial fibrillation (AF), clots may form in the left atrium. This, in turn, may lead to embolization of the clot, with resulting ischemic stroke or systemic embolism. Also, the presence of AF confers a fivefold increased risk for stroke. AF is the most common and important cause of stroke resulting from any cause. This article considers the risks for and anticoagulation prophylaxis against embolic stroke in patients with AF.
Collapse
Affiliation(s)
- Albert L Waldo
- Department of Medicine, Division of Cardiovascular Medicine, Case Western Reserve University/University Hospitals of Cleveland Case Medical Center, Cleveland, OH, USA.
| |
Collapse
|
262
|
Abstract
Atrial fibrillation (AF), an increasingly common dysrhythmia, is responsible for substantial morbidity and mortality. Currently in the United States, approximately 2.3 million people are diagnosed with AF and, based on the census, this number may rise to 5.6 million by 2050. Risk factors for AF include advancing age and cardiovascular disease and its risk factors. The chief hazard of AF is embolic stroke, which is increased four- to fivefold, assuming great importance in advanced age when it becomes a dominant factor. AF is associated with about a doubling of mortality.
Collapse
Affiliation(s)
- William B Kannel
- Boston University, The Framingham Heart Study, 73 Mount Wayte Avenue, Framingham, MA 01702, USA.
| | | |
Collapse
|
263
|
Mainardi L, Sörnmo L, Cerutti S. Understanding Atrial Fibrillation: The Signal Processing Contribution, Part II. ACTA ACUST UNITED AC 2008. [DOI: 10.2200/s00153ed1v01y200809bme025] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
264
|
Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, Colletti A, Pensabene O, Lisi F, Vasquez L, Grammatico A, Boriani G. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 2008; 155:100-7, 107.e1. [PMID: 18082498 DOI: 10.1016/j.ahj.2007.08.033] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2007] [Accepted: 08/30/2007] [Indexed: 01/06/2023]
Abstract
BACKGROUND Rhythm control is an important goal in the treatment of recurrent atrial tachyarrhythmias (AT). The PITAGORA study was a randomized trial in patients paced for sinus node disease (SND), designed to test the noninferiority of class IC antiarrhythmic drugs (AADs) to amiodarone in terms of a primary end point composed of death, permanent AT, cardiovascular hospitalization, atrial cardioversion, or AAD change. METHODS Randomization was stratified to assign 2 patients to amiodarone and 2 patients to class IC AADs: propafenone or flecainide. One hundred seventy-six patients (46% men, 72 +/- 8 years) were enrolled. Device diagnostics continuously monitored AT recurrences and duration. RESULTS In a mean follow-up of 20 +/- 9 months, the primary end point occurred in 23 (30.7%) of 75 class IC patients and in 28 (40.0%) of 70 amiodarone patients. The absolute difference in the end point incidence (-9.3%; 95% CI between 3.7% and -22.3%) confirmed the noninferiority of class IC to amiodarone (P = .007). Kaplan-Meier 1-year freedom from AT episodes >10 minutes, 1 day, and 7 days was 40%, 73%, and 91% for amiodarone and 28%, 78%, and 86% for class IC AADs (P = nonsignificant). CONCLUSIONS In patients paced for SND and suffering from AT, class IC AADs proved not to be inferior to amiodarone in terms of the primary composite end point described or end points which were differently composed of mortality, efficacy, or AAD side effects. The AADs studied also showed similar results in terms of symptoms, quality of life, and freedom from AT recurrences.
Collapse
|
265
|
Nieuwlaat R, Eurlings LW, Capucci A, Crijns HJ. Atrial fibrillation in the ‘real world’: undecided issues. Eur Heart J Suppl 2007. [DOI: 10.1093/eurheartj/sum067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
266
|
Saksena S, Hettrick DA, Koehler JL, Grammatico A, Padeletti L. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J 2007; 154:884-92. [PMID: 17967594 DOI: 10.1016/j.ahj.2007.06.045] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2007] [Accepted: 06/11/2007] [Indexed: 10/22/2022]
Abstract
INTRODUCTION The experimental concept that "atrial fibrillation (AF) begets AF" implies that atrial tachyarrhythmia (AT)/AF burden uniformly increases over time. However, the temporal patterns of paroxysmal AT/AF burden progression, its conversion to persistent AF, and the relationship to underlying disease in humans are unknown. We analyzed the average daily AT/AF burden in patients with concomitant bradycardia and paroxysmal AF to examine these issues. METHODS Three hundred thirty patients with a history of paroxysmal AF (mean age 70 +/- 10 years; 61% male) were implanted with a pacemaker that automatically recorded the cumulative daily AT/AF burden. Persistent AT/AF was defined as 7 consecutive days with >23 hours of AT on the device data logs. Antiarrhythmic drug therapy was required to be stable for at least 7 months. RESULTS Average follow-up was 401 +/- 123 days. Seventy-eight patients (24%) progressed to persistent AT/AF during the follow-up period with a mean interval of 147 +/- 149 days. Mean AT/AF burden increased progressively (slope 14 s/d, P < .001) over 500 days after implant, and median AT/AF burden also increased (P < .01) in this subgroup of patients. This increase was highly correlated with the presence of structural heart disease (P < .001). There was a concomitant decrease in atrial premature beat (APB) frequency. Most patients transitioning to persistent AF were in sinus rhythm with minimal AT/AF burden in the days immediately before persistent AF. Neither mean nor median AT/AF burden increased over time in patients remaining in paroxysmal AF (slope 0 s/d, P = .7) despite a higher APB frequency than in patients with heart disease (P =.003) and a higher likelihood of daily AT/AF events (P < .001). CONCLUSIONS Temporal patterns of AT/AF burden in patients developing persistent AF show a progressive increase with a sudden transition to persistent AF. This is more consistent with substrate changes, rather than increased density of triggering APBs or paroxysmal AT/AF events. Thus, progression to persistent AF is probably related to an AF substrate, which is undergoing progressive structural remodeling owing to heart disease and other factors and is now suddenly capable of sustaining prolonged or multiple ATs. Therapies directed at the atrial substrate may be needed to prevent persistent AF.
Collapse
|
267
|
Zacà V, Galderisi M, Mondillo S, Focardi M, Ballo P, Guerrini F. Left atrial enlargement as a predictor of recurrences in lone paroxysmal atrial fibrillation. Can J Cardiol 2007; 23:869-72. [PMID: 17876377 PMCID: PMC2651363 DOI: 10.1016/s0828-282x(07)70841-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND A mild increase in left atrial (LA) size predicts arrhythmia onset and adverse events in patients with lone paroxysmal atrial fibrillation (LPAF). However, the role of LA size as a predictor of LPAF recurrences is still controversial. OBJECTIVE The potential role of LA size in affecting the frequency of recurrent episodes in patients with LPAF was investigated. METHODS Fifty-one patients who were admitted for a first episode of LPAF and presenting with one recurrence (group A, n=20), two or three recurrences (group B, n=18), or four or more recurrences (group C, n=13) during an average follow-up period of two years were retrospectively selected. The M-mode LA anteroposterior diameter (LAAPd) was used as an echocardiographic surrogate of LA size. RESULTS At baseline, LA size was normal or borderline in the control group, group A and group B, but significantly increased in group C. At two years' follow-up, a significant further LA enlargement from baseline was observed in group B (LAAPd 40+/-1.1 mm versus 40.7+/-1.2 mm, P<0.01) and in group C (LAAPd 41.4+/-1.6 mm versus 42.7+/-1.7 mm, P<0.001), while LA size remained substantially unchanged in the control group and in group A. CONCLUSIONS Observations confirmed the association of increased LA size and LPAF onset, and provide the first evidence for a potential role of LA progressive enlargement as a predictor of arrhythmic recurrences.
Collapse
Affiliation(s)
- Valerio Zacà
- Department of Cardiology, University of Siena, Siena
- Correspondence: Dr Valerio Zacà, Department of Cardiology, University of Siena, Viale Bracci 1, 53100, Siena, Italy. Telephone 39-0577-585379, fax 39-0277-233112, e-mail
| | - Maurizio Galderisi
- Cardioangiology Unit, Department of Clinical and Experimental Medicine, Federico II University, Naples
| | | | - Marta Focardi
- Department of Cardiology, University of Siena, Siena
| | - Piercarlo Ballo
- Cardiology Operative Unit, S Andrea Hospital, La Spezia, Italy
| | | |
Collapse
|
268
|
Budeus M, Hennersdorf M, Reinsch N, Wieneke H, Sack S, Erbel R. Prediction of Atrial Fibrillation with Atrial Late Potentials and Pathological Chemoreflexsensitivity. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2007; 30:1254-61. [PMID: 17897128 DOI: 10.1111/j.1540-8159.2007.00847.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Atrial fibrillation (AF) is a very common arrhythmia that often causes the serious complication of a stroke. OBJECT The aim was to evaluate the utility of pathological chemoreflexsensitivity (PCHRS) and atrial late potentials (ALP) to predict AF in follow-up. METHODS We investigated a prospective study on the basis of our observation about a PCHRS and ALP in paroxysmal AF. The PCHRS was predefined as a chemoreflexsensitivity below 3.0 ms/mmHg and ALP were predefined as a filtered P-wave duration > or =120 ms and a root mean square voltage of the last 20 ms of the P-wave < or =3.5 microV. A P-wave triggered P-wave signal averaged electrocardiograph (ECG) and chemoreflexsensitivity was performed on 250 consecutive patients who were divided into four groups. Group I consisted of patients with ALP and PCHRS, patients of group II had only ALP, a PCHRS was only present in group III, and patients of group IV had neither ALP nor PCHRS. RESULTS During the mean follow-up of 37.8 months AF was observed in 10 patients (4%). The patients of the four groups were similar according to clinical baseline characteristics. The incidence of AF was higher in group I (18% of patients) than in group II (6% of patients, P = 0.229) and significantly higher than in group III (3% of patients, P = 0.034) or group IV (1% of patients, P < 0.0001). Patients with ALP and PCHRS showed a 33-fold risk (P < 0.001) for the onset AF. CONCLUSIONS The results of our study suggest that the probability of AF could be predicted with a P-wave signal averaged ECG and an analysis of chemoreflexsensitivity. The predictive power of the combination of ALP and PCHRS seemed not high enough for risk stratification.
Collapse
Affiliation(s)
- Marco Budeus
- Department of Cardiology, West-German Heart Centre, University of Duisburg-Essen, Germany.
| | | | | | | | | | | |
Collapse
|
269
|
Ricci RP, Russo M, Santini M. Management of atrial fibrillation--what are the possibilities of early detection with home monitoring? Clin Res Cardiol 2007; 95 Suppl 3:III10-6. [PMID: 16598598 DOI: 10.1007/s00392-006-1303-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A large number of patients implanted with dual-chamber pacemakers exhibit symptoms of recurrent or new atrial fibrillation. Scheduling follow-up visits for every 6-12 months in this setting may be disadvantageous on three grounds. First, delayed information about the onset of atrial fibrillation does not allow an immediate reaction with pharmacological or dedicated pacing therapy. Second, the efficacy of the chosen therapy cannot be evaluated until the next scheduled follow-up. Third, real-time awareness of a significant atrial fibrillation burden is critical to use appropriate anticoagulation therapy for the prevention of thromboembolic events. The new Home Monitoring technology (Biotronik, Berlin) offers real-time transmission of diagnostic data stored in the pacemaker memory to the physician. This may represent a useful tool for the detection and treatment of patients with atrial fibrillation. Daily documentation of atrial rhythm via Home Monitoring allows a quick reaction to the onset of atrial fibrillation and real-time control of the therapeutic efficacy. The ongoing, international, randomized Home-PAT clinical trial aims at defining and quantifying the importance of Home Monitoring for the diagnosis and treatment of atrial fibrillation in patients with dual-chamber pacemakers.
Collapse
Affiliation(s)
- R P Ricci
- Department of Cardiology, San Filippo Neri Hospital, Via Martinotti, 20, 00135 Rome, Italy.
| | | | | |
Collapse
|
270
|
Syed TM, Halperin JL. Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges. ACTA ACUST UNITED AC 2007; 4:428-35. [PMID: 17653115 DOI: 10.1038/ncpcardio0933] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2006] [Accepted: 04/24/2007] [Indexed: 11/09/2022]
Abstract
Atrial fibrillation (AF) is a major risk factor for disabling ischemic strokes. Anticoagulation is highly effective for stroke prevention in patients with AF, but a substantial number of patients are unable to sustain chronic therapy with warfarin. Most strokes in patients with AF are thought to arise from thrombus formation in the left atrial appendage (LAA); therefore, occlusion of the orifice of the LAA provides a theoretically appealing option for stroke prevention. Surgical exclusion of the LAA is increasingly performed in patients undergoing open-heart surgery, and thoracoscopic epicardial occlusion of the LAA has yielded promising early results. Percutaneous LAA occlusion devices have shown some success initial trials, but additional safety and efficacy data are required before this approach can be routinely considered. Here we discuss the LAA in relation to AF-related embolic stroke, and how LAA occlusion devices could be used in stroke prevention in patients who cannot tolerate chronic anticoagulant therapy.
Collapse
Affiliation(s)
- Tariqshah M Syed
- Department of Cardiology, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029-6574, USA
| | | |
Collapse
|
271
|
Ghali JK, Orlov MV, Araghi-Niknam M, Sherfesee L, Hettrick DA. The Influence of Symptoms and Device Detected Atrial Tachyarrhythmias on Medical Management: Insights from A-HIRATE. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2007; 30:850-7. [PMID: 17584266 DOI: 10.1111/j.1540-8159.2007.00772.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The influence of symptoms and device-detected atrial tachyarrhythmias (AT) on the management of AT in a pacemaker population has not been well described. We report the influence of symptoms and device detected AT on pharmacological disease management. METHODS Group 1 (n = 331) included patients without and Group 2 (n = 96) included patients with prior history of AT with an approved pacemaker indication. Dual chamber pacemakers, (kappa 700 or kappa 900, Medtronic, Minneapolis, MN, USA) were implanted. The impact of symptoms, AT burden, a history of AT, and time since implant on changes in the use of anticoagulation, beta-blockers, and antiarrhythmic drugs was analyzed. RESULTS A total of 232 patients experienced at least one atrial high rate episode (AHRE). AT burden was higher in Group 2. Symptoms were reported by 154 patients in Group 1 and 47 patients in Group 2. Among patients experiencing AHRE, symptoms were reported in 17 patients in Group 1 (5.3%) and 22 patients in Group 2 (24.7%). Changes in antiarrhythmic drugs and anticoagulation were influenced by history of AT and AT burden, while changes in the use of beta-blockers were influenced by symptoms. The probability of a pharmacologic therapy change decreased with time since implant for all agents except coumadin. CONCLUSION Pharmacologic AT therapy is differentially influenced by patient-reported symptoms of AT compared to device-detected asymptomatic AT. Anticoagulation and antiarrhythmic therapies are influenced by device detection of asymptomatic AT, whereas initiation of beta-blockers is more strongly influenced by symptoms.
Collapse
Affiliation(s)
- Jalal K Ghali
- University Health Center, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | | | | | | | | |
Collapse
|
272
|
Boriani G, Padeletti L, Santini M, Gulizia M, Orazi S, Botto G, Capucci A, Biffi M, Martignani C, Ricci R, Vimercati M, DiStefano P, Grammatico A. Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. Am Heart J 2007; 154:193-200. [PMID: 17584576 DOI: 10.1016/j.ahj.2007.04.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Accepted: 04/01/2007] [Indexed: 02/07/2023]
Abstract
BACKGROUND In sinus node disease (SND) atrial tachyarrhythmias (ATs) may frequently occur, after implant of a pacemaker for bradycardia, and are to be managed by rate or rhythm control. METHODS We evaluated ventricular heart rate (HR) during AT, AT-related symptoms and hospitalizations in 333 patients who received DDDRP pacemakers for SND. RESULTS In days with 24 hours of AT, mean daily HR during AT was > 80, 90, 100, 110, and 120 beats per minute (bpm) in 191 (57%), 114 (34%), 55 (16%), 23 (7%), and 11 (3%) patients, respectively. The proportion of patients with a mean daily HR > 80 bpm during AT despite the use of rate control agents was 28% among patients treated with calcium-channel blockers, 43% with digoxin, 49% with a combination of agents, 54% with amiodarone, 64% with sotalol, and 69% with beta blockers. Patients with HR > 100 bpm experienced a higher prevalence of both AT-related hospitalizations and cardiovascular hospitalizations than those with HR < or = 100 bpm (36% vs 21%, P = .013; 42% vs 28%, P = .003) and a significantly higher number of AT-related symptoms (1.8 +/- 0.9 vs 1.4 +/- 1.0, P = .008). CONCLUSIONS Limited attention has been dedicated to rate control in patients with pacemaker. This is the first study to evaluate the prevalence and implications of inappropriate rate control in patients with pacemaker. We found that in a substantial proportion of patients with SND who have recurrent ATs despite pacing, mean daily HR during AT is high and that these patients present increased hospitalizations and more symptoms, thus suggesting the need to improve rate control.
Collapse
Affiliation(s)
- Giuseppe Boriani
- Institute of Cardiology, University of Bologna and Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
273
|
Verma A, Minor S, Kilicaslan F, Patel D, Hao S, Beheiry S, Lakkireddy D, Elayi SC, Cummings J, Martin DO, Burkhardt JD, Schweikert RA, Saliba W, Tchou PJ, Natale A. Incidence of Atrial Arrhythmias Detected by Permanent Pacemakers (PPM) Post-Pulmonary Vein Antrum Isolation (PVAI) for Atrial Fibrillation (AF): Correlation with Symptomatic Recurrence. J Cardiovasc Electrophysiol 2007; 18:601-6. [PMID: 17428271 DOI: 10.1111/j.1540-8167.2007.00789.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Studies examining AF recurrences post-PVAI base recurrence on patient reporting of symptoms. However, whether asymptomatic recurrences are common is not well known. OBJECTIVE To assess the incidence of atrial tachycardia/fibrillation post-PVAI as detected by a PPM and whether these recurrences correlate to symptomatic recurrence. METHODS Eighty-six consecutive patients with symptomatic AF and PPMs with programmable mode-switch capability underwent PVAI. Mode switching was programmed post-PVAI to occur at an atrial-sensed rate of >170 bpm. Patients were followed with clinic visits, ECG, and PPM interrogation at 1, 3, 6, and 9 months post-PVAI. The number and duration of mode-switching episodes (MSEs) were recorded at each visit and is presented as median (interquartile range). RESULTS The patients (age 57 +/- 8 years, EF 54 +/- 10%) had paroxysmal (65%) and persistent (35%) AF pre-PVAI. Sensing, pacing, and lead function were normal for all PPMs at follow-up. Of the 86 patients, 20 (23%) had AF recurrence based on symptoms. All 20 of these patients had appropriate MSEs detected. Of the 66 patients without symptomatic recurrence, 21 (32%) had MSEs detected. In 19 of these patients, MSEs were few in number, compared with patients with symptomatic recurrence (16 [4-256] vs 401 [151-2,470], P < 0.01). The durations were all <60 seconds. All of these nonsustained MSEs occurred within the first 3 months post-PVAI, gradually decreasing over time. The other 2 of 21 remaining patients had numerous (1,343 [857-1,390]) and sustained (18 +/- 12 minutes) MSEs that also persisted beyond 3 months (1 beyond 6 months). Therefore, the incidence of numerous, sustained MSEs in asymptomatic patients post-PVAI was 2 of 66 (3%). CONCLUSIONS Detection of atrial tachyarrhythmias by a PPM occurred in 30% of patients without symptomatic AF recurrence. Most of these episodes were <60 seconds and waned within 3 months. Sustained, asymptomatic episodes were uncommon.
Collapse
Affiliation(s)
- Atul Verma
- Cleveland Clinic Foundation, Section of Electrophysiology, Cleveland, Ohio 44195, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
274
|
Kirchhof P, Breithardt G. New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. Heart Rhythm 2007; 4:790-3. [PMID: 17556206 DOI: 10.1016/j.hrthm.2007.01.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2006] [Accepted: 01/15/2007] [Indexed: 11/26/2022]
Abstract
Atrial fibrillation (AF) is a chronic, often progressive disease. Despite the ongoing concerted effort to improve AF therapy, often there is no remedy for curing AF and preventing the deleterious effects of the arrhythmia on health. Antiarrhythmic drug therapy is likely to remain the mainstay of therapy for many patients in the foreseeable future. Available antiarrhythmic drugs are moderately effective, which is important for patients who respond, especially given the chronic and often progressive nature of the disease. This article describes emerging concepts under clinical evaluation that attempt to improve the safety of available antiarrhythmic drugs in the treatment of recurrent AF. Two concepts are reviewed: (1) combination of an antiarrhythmic drug with a calcium channel blocker to reduce proarrhythmic side effects, and (2) "intelligent" reduction of the duration of antiarrhythmic drug therapy targeted to periods of symptomatic or likely AF recurrence.
Collapse
Affiliation(s)
- Paulus Kirchhof
- Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany.
| | | |
Collapse
|
275
|
Budeus M, Hennersdorf M, Felix O, Reimert K, Perings C, Wieneke H, Erbel R, Sack S. Prediction of atrial fibrillation in patients with cardiac dysfunctions†. ACTA ACUST UNITED AC 2007; 9:601-7. [PMID: 17507361 DOI: 10.1093/europace/eum054] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
AIMS Atrial fibrillation (AF) is a common arrhythmia in advanced heart failure. The occurrence of AF increases the risk of death and hospitalization for patients with heart failure. The results of different studies indicated that patients with paroxysmal AF have a longer filtered P wave duration (FPD), a lower root mean square voltage of the last 20 ms of the P wave (RMS 20), and a lower chemoreflexsensitivity (CHRS). Our study bases on these observations in order to examine the methods for predicting AF in patients with a left ventricular ejection fraction below 40% without a prior documentation of AF. METHODS AND RESULTS The ratio between the difference of RR intervals in ECG and venous pO(2) before and after 5-min oxygen inhalation was measured (ms/mmHg) in order to determine the CHRS. A P wave signal-averaged ECG was performed for the measurement of FPD and RMS 20. The measurements were only performed in 94 patients with sinus rhythm. AF occurred during the mean follow-up of 39.9 months in 24 patients (26%). There were no significant differences concerning age, heart diseases, sex, ejection fraction, heart rate, or the use of drugs. The FPD (130.3 +/- 4.2 vs. 118.9 +/- 12.4 ms, P < 0.0001) was significantly longer and the RMS 20 (3.03 +/- 0.95 vs. 3.83 +/- 1.58 microV, P = 0.02) was significantly lower in patients with AF than in sinus rhythm. The CHRS did not differ significantly between both groups (3.57 +/- 1.49 vs. 3.48 +/- 1.62 ms/mmHg, P = 0.81). The chi(2) test showed that the threshold of FPD>or=125 ms and RMS 20 <or=3.3 microV revealed the best predictive value for AF. A stepwise logistic regression analysis of all variables identified the threshold of FPD>or=125 ms and RMS 20 <or=3.3 microV (OR 18.71; 95% CI, 4.85-72.16, P < 0.0001) as independent predictors for AF. CONCLUSIONS In summary, our data show that the results of a P wave signal-averaged ECG can predict the risk for new onset of AF in patients with heart failure. The value of signal-averaged FPD is probably the result of reflecting the intra-atrial conduction delay, which is a pathophysiological condition for AF. The CHRS is not a suitable method for predicting AF.
Collapse
Affiliation(s)
- Marco Budeus
- Department of Cardiology, West-German Heart Centre, University of Duisburg-Essen, Hufeland Street 55, Essen 45122, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
276
|
Klingenheben T, Israel CW. Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy. Herzschrittmacherther Elektrophysiol 2007; 17:225-8. [PMID: 17211755 DOI: 10.1007/s00399-006-0539-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2006] [Accepted: 11/16/2006] [Indexed: 11/25/2022]
Abstract
We present the case of a patient with highly symptomatic tachyarrhythmias for 2 years without any arrhythmia documentation despite numerous ECG and Holter registrations. By means of telemedicine, it was possible to document the arrhythmia--in this case atrial fibrillation--within 10 days and to start antiarrhythmic drug treatment with flecainide and metoprolol. This case demonstrates the diagnostic potential of telemedicine in patients with recurrent episodes of tachyarrhythmias in whom episodes are not sufficiently frequent to allow diagnosis by Holter monitoring. Telemedicine may also be advantageous for ECG monitoring during the early phase after cardioversion or initiation of specific antiarrhythmic pharmacotherapy in order to detect potential drug-induced proarrhythmic changes.
Collapse
Affiliation(s)
- T Klingenheben
- Praxis für Kardiologie, Alfred-Bucherer-Strasse 6, 53115 Bonn, Germany.
| | | |
Collapse
|
277
|
Silberbauer J, Sulke N. The role of pacing in rhythm control and management of atrial fibrillation. J Interv Card Electrophysiol 2007; 18:159-86. [PMID: 17473977 DOI: 10.1007/s10840-007-9087-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2006] [Accepted: 02/01/2007] [Indexed: 11/28/2022]
Abstract
Atrial fibrillation is the most common sustained cardiac arrhythmia and is increasing in prevalence with an ageing population. As the arrhythmia is often asymptomatic the true prevalence is likely even higher. Largely because of stroke this arrhythmia places a huge financial burden on the health economy. Despite this, large studies assessing rate versus rhythm control have been equivocal. Because of the ineffectiveness of pharmacological therapy much research effort has been undertaken in device and ablative approaches to rhythm management. Although catheter ablation has gained favour because of the high success rates the technique requires considerable expertise and still has a significant complication profile maintaining interest in pacing therapies for atrial fibrillation. Dual chamber versus single-chamber ventricular pacing has been shown to significantly reduce the incidence of atrial fibrillation. Research is currently underway to see if minimising the deleterious effects of right ventricular apical pacing could further increase the benefits of atrioventricular synchronous pacing. Several studies show some (albeit variable) reduction in AF burden with anti-AF algorithms in the setting of bradycardia. Antitachycardia pacing, on the other hand, has not been shown to treat AF in a randomised trial despite the successful termination of co-existent atrial tachycardias. There is increasing evidence that alternative atrial pacing sites may treat AF by improving atrial function. Furthermore, these strategies coupled with other therapies in a 'hybrid approach' have also showed promising results.
Collapse
Affiliation(s)
- John Silberbauer
- Eastbourne General Hospital East Sussex Hospitals NHS Trust, Eastbourne, BN21 2UD, UK
| | | |
Collapse
|
278
|
Arya A, Piorkowski C, Sommer P, Kottkamp H, Hindricks G. Clinical Implications of Various Follow Up Strategies After Catheter Ablation of Atrial Fibrillation. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2007; 30:458-62. [PMID: 17437567 DOI: 10.1111/j.1540-8159.2007.00693.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Arash Arya
- Department of Electrophysiology, University of Leipzig, Heart Center, Leipzig, Germany.
| | | | | | | | | |
Collapse
|
279
|
Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in Anticoagulation for Atrial Fibrillation in the U.S. J Am Coll Cardiol 2007; 49:1561-5. [PMID: 17418296 DOI: 10.1016/j.jacc.2006.11.045] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2006] [Revised: 11/20/2006] [Accepted: 11/27/2006] [Indexed: 11/20/2022]
Abstract
OBJECTIVES The purpose of this study was to track trends in the use of anticoagulation for atrial fibrillation (AF) over the past decade and identify predictors of use. BACKGROUND Atrial fibrillation is common and associated with significant morbidity. Previous studies suggest underuse of anticoagulant therapy in patients with AF. METHODS The National Ambulatory Medical Care Survey database was queried for all patient visits with a diagnosis of AF between 1994 and 2003. Other diagnoses, other medications, and demographic, visit, geographic, and provider characteristics were compared with the prescription of anticoagulation in predefined age and risk groups. RESULTS The prevalence of the diagnosis of AF and anticoagulation for AF has increased over the last decade. Increased age and use of rate control agents is associated with the use of anticoagulation. There is a trend toward less anticoagulation when a rhythm control agent is used instead of a rate control agent. Anticoagulation might be overused in a group of low-risk patients. CONCLUSIONS From 1995 through 2002, an increase has occurred in anticoagulation for AF, especially in those at highest risk for thromboembolic phenomena. A substantial number of patients at risk for thromboembolic events are not anticoagulated, and further studies are needed to determine how many of these patients are candidates for anticoagulation. Anticoagulation use has increased in nontargeted, low-risk groups in whom antiplatelet agents are appropriate. Use of a rhythm control agent might be associated with less use of anticoagulation.
Collapse
Affiliation(s)
- Shane B Rowan
- Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262, USA
| | | | | | | |
Collapse
|
280
|
Rao BH, Saksena S. Impact of "hybrid therapy" on long-term rhythm control and arrhythmia related hospitalizations in patients with drug-refractory persistent and permanent atrial fibrillation. J Interv Card Electrophysiol 2007; 18:127-36. [PMID: 17372812 DOI: 10.1007/s10840-007-9091-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2006] [Accepted: 02/15/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND Recently, a "hybrid therapy" strategy has been used for successful rhythm control in persistent and permanent atrial fibrillation (AF) patients. The impact of this strategy on arrhythmia recurrences and subsequent AF related hospitalizations are unknown. MATERIALS AND METHODS Forty-seven patients (66 +/- 10 years) with symptomatic persistent (N = 26) or permanent (N = 21) AF underwent "hybrid therapy" and were followed for 24 +/- 15 months. All patients underwent linear right atrial ablation and implantation of pacemaker or atrioventricular defibrillator (AVICD) capable of continuous right atrial pacing with previously ineffective antiarrhythmic drug therapy for AF prevention. Device data-logs were used to monitor AF recurrences. RESULTS Freedom from permanent AF was 97, 90, and 83% at 6 months, 2 and 3 years, respectively. Sixteen patients (34%) had no recurrent AF after "hybrid therapy." Thirty-one patients (66%) had a total of 55 AF recurrences (mean 1.8 per patient). There was a significant reduction in the mean AF related hospitalizations (from 3.5 +/- 2.8 to 0.57 +/- 1.1 per patient), cardioversion hospitalizations (from 3.5 +/- 2.2 to 0.38 +/- 0.5 per patient) and DC cardioversions (from 3.1 +/- 3.9 to 0.7 +/- 0.5 per patient) after hybrid therapy compared to event rates before therapy (p < 0.05 for all). CONCLUSIONS Rhythm control improves significantly with hybrid therapy in patients with persistent and permanent AF refractory to drugs and cardioversion therapy. This improvement is associated with a significant reduction in AF related hospitalizations and need for cardioversion therapy.
Collapse
Affiliation(s)
- B Hygriv Rao
- Electrophysiology Research Foundation, Warren, NJ 07059, USA
| | | |
Collapse
|
281
|
Orlov MV, Ghali JK, Araghi-Niknam M, Sherfesee L, Sahr D, Hettrick DA. Asymptomatic Atrial Fibrillation in Pacemaker Recipients: Incidence, Progression, and Determinants Based on the Atrial High Rate Trial. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2007; 30:404-11. [PMID: 17367361 DOI: 10.1111/j.1540-8159.2007.00682.x] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The epidemiology and clinical implications of asymptomatic atrial tachyarrhythmias (AT) including both atrial fibrillation and flutter in pacemaker recipients with and without arrhythmia history are not well understood. The Atrial High Rate Episodes (A-HIRATE) in Pacemaker Patients Trial was designed to identify and compare the incidence of AT in patients with and without previously diagnosed AT and a standard indication for dual chamber pacing, and to provide useful diagnostic information for clinical management. METHODS Four hundred twenty-seven patients were implanted with a pacemaker (Kappa 7-900, Medtronic, Inc., Minneapolis, MN, USA) capable of detecting and storing multiple atrial high rate episodes (AHRE) and followed for 2 years. Group I included 331 patients without prior history of AT and Group II included 96 patients with prior AT history. RESULTS Pacemaker diagnostics appropriately detected 93% of reviewed AHRE. The rate of occurrence of first AHRE was significantly higher (P < 0.0001) in Group II patients, as was average AHRE burden. The rate of first AHRE occurrence was 88.6% for patients in Group II and 53.8% in Group I at 24 months post-implant. The rate of AHRE occurrence was similar in both groups after the first month post-implant. The majority of stored AHRE were asymptomatic; symptoms did not correspond to an actual AHRE in most patients. CONCLUSIONS The incidence of AT in pacemaker recipients is high. Most device-detected AHRE are asymptomatic. Prior history of AT is associated with higher arrhythmia burden. AHRE diagnostics have a high positive predictive value for identifying AT events.
Collapse
Affiliation(s)
- Michael V Orlov
- Tufts University School of Medicine, Boston, Massachusetts 02135, USA.
| | | | | | | | | | | |
Collapse
|
282
|
de Voogt WG, van Hemel NM, van de Bos AA, Koïstinen J, Fast JH. Verification of pacemaker automatic mode switching for the detection of atrial fibrillation and atrial tachycardia with Holter recording. Europace 2007; 8:950-61. [PMID: 17043069 DOI: 10.1093/europace/eul112] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
AIMS Verification of the accuracy of onset, offset, and duration of automatic mode switching (AMS) of pacemakers compared with onset and end of atrial fibrillation (AF) or atrial tachycardia (AT). Correct pacemaker diagnosis of atrial tachyarrhythmias (AA) is indispensable for reliable automatic prevention and intervention algorithms of AA. METHODS AND RESULTS Comparison was made of the AMS registration of the pacemaker-stored electrograms (EGMs) and the number and cumulative duration of these episodes with continuous 7-day Holter monitoring. Atrial sensitivity was kept at 0.5 mV and far field R-wave recognition in the atrial channel was excluded by blanking of this signal. Lead types were confined to leads with short-ring tip spacing (10-13.8 mm). During Holter monitoring, 18 of 57 included patients with standard reason for pacemaker implantation showed episodes of AF or AT. Cumulative duration of AF and AT from Holter was correctly interpreted by the pacemaker in 99.9% of the patients. All episodes of AF, as seen on the Holter recording, were recognized by the pacemaker (correlation 99.9%). During AF, multiple episodes of undersensing were detected. The number of AMS episodes was influenced by undersensing during AF. The influence of these short episodes of undersensing on the total duration of AF was trivial (cumulative duration of AF was 99.9% correct). In patients with AT without AF on Holter (n=7) and in contrast to the AF episodes, the cumulative AT duration did not correlate well (63%) with the Holter recordings. The number of AMS episodes in the setting of AT was influenced by the atrial tachycardia detection rate setting and the duration of the post-ventricular atrial blanking interval. CONCLUSION The total duration of AF is correctly represented by the total duration of AMS and can be considered a reliable measure of total AF duration. AT duration was poorly correlated with AMS duration. The number of mode switches does not reflect the number of episodes of AF/AT. Increased memory capacity allowing the storing of all EGMs triggered by the initiation of AF/AT would be the ideal setting with which to optimize the diagnostic performance of pacemakers.
Collapse
Affiliation(s)
- Willem G de Voogt
- Department of Cardiology, St Lucas Andreas Hospital, J. Tooropstraat 164, 1061 AE Amsterdam, The Netherlands.
| | | | | | | | | |
Collapse
|
283
|
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2007; 27:1979-2030. [PMID: 16885201 DOI: 10.1093/eurheartj/ehl176] [Citation(s) in RCA: 362] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
284
|
Atarashi H, Ogawa S, Inoue H, Hamada C. Dose-Response Effect of Flecainide in Patients With Symptomatic Paroxysmal Atrial Fibrillation and/or Flutter Monitored With Trans-Telephonic Electrocardiography A Multicenter, Placebo-Controlled, Double-Blind Trial. Circ J 2007; 71:294-300. [PMID: 17322624 DOI: 10.1253/circj.71.294] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND A double-blind, randomized, parallel-group, placebo-controlled trial was conducted in patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide. METHODS AND RESULTS A total of 143 patients at 30 centers were randomized to receive 25, 50, or 100 mg of flecainide or placebo twice daily (BID). In 123 patients (per protocol set), those remaining free from PAF/PAFL after the treatment were 3.1% on placebo, 7.7% on 25 mg/BID, 9.4% on 50 mg/BID, and 39.4% on 100 mg/BID of flecainide. As a whole group, a significant linear dose-response (p<0.001) was observed and a significant difference between placebo and 100 mg/BID was observed (p<0.001). A similar dose-response between the present study and Caucasian study was demonstrated. Although there were 5 patients who needed cardioversion or ablation because of frequent episodes of PAF/PAFL (2 in 25 mg/BID, 1 in 50 mg/BID, and 2 in 100 mg/BID of flecainide), neither death nor ventricular proarrhythmic event was reported. CONCLUSIONS This study indicated that flecainide exerted a significant dose-dependent effect on the prevention of symptomatic PAF/PAFL recurrence and showed that there was no inter-ethnic difference in the clinical effect of flecainide in patients with PAF/PAFL.
Collapse
Affiliation(s)
- Hirotsugu Atarashi
- Department of Internal Medicine, Nippon Medical School, Tama-Nagayama Hospital, Japan.
| | | | | | | |
Collapse
|
285
|
Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007; 39:371-91. [PMID: 17701479 DOI: 10.1080/07853890701320662] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Atrial fibrillation (AF) is said to be an epidemic, affecting 1%-1.5% of the population in the developed world. The clinical significance of AF lies predominantly in a 5-fold increased risk of stroke. Strokes associated with AF are usually more severe and confer increased risk of morbidity, mortality, and poor functional outcome. Despite the advent of promising experimental therapies for selected patients with acute stroke, pharmacological primary prevention remains the best approach to reducing the burden of stroke. New antithrombotic drugs include both parenteral agents (e.g. a long-acting factor Xa inhibitor idraparinux) and oral anticoagulants, such as oral factor Xa inhibitors and direct oral thrombin inhibitors (ximelagatran, dabigatran). Ximelagatran had shown significant potential as a possible replacement to warfarin therapy, but has been withdrawn because of potential liver toxicity. Its congener dabigatran appears to have a better safety profile and has recently entered a phase III randomized clinical trial in AF. Oral factor Xa inhibitors (rivaroxaban, apixaban, YM150) inhibit factor Xa directly, without antithrombin III mediation, and may prove to be more potent and safe. Selective inhibitors of specific coagulation factors involved in the initiation and propagation of the coagulation cascade (factor IXa, factor VIIa, circulating tissue factor) are at an early stage of development. Additional new agents with hypothetical, although not yet proven, anticoagulation benefits include nematode anticoagulant peptide (NAPc2), protein C derivatives, and soluble thrombomodulin. A battery of novel mechanical approaches for the prevention of cardioembolic stroke has recently been evaluated, including various models of percutaneous left atrial appendage occluders which block the connection between the left atrium and the left atrial appendage, minimally invasive surgical isolation of the left atrial appendage, and implantation of the carotid filtering devices which divert large emboli from the internal to the external carotid artery, preventing the embolic material from reaching intracranial circulation. Despite recent advances and promising new approaches, prevention of recurrent AF may be one of the best protections against AF-related stroke and may reduce the prevalence of stroke by almost 25%. Improved pharmacological and nonpharmacological rhythm control strategies for AF as well as primary prevention of AF with 'upstream' therapy and risk factor modification are likely to produce a larger effect on the reduction of stroke rates in the general population than will specific interventions.
Collapse
|
286
|
Rucinski P, Rubaj A, Kutarski A. Pharmacotherapy changes following pacemaker implantation in patients with bradycardia-tachycardia syndrome. Expert Opin Pharmacother 2007; 7:2203-13. [PMID: 17059377 DOI: 10.1517/14656566.7.16.2203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The management of bradycardia-tachycardia syndrome (BTS) includes bradycardia and tachyarrhythmia therapy. At present, the treatment for symptomatic bradycardia in BTS patients is permanent cardiac pacing. The pharmacological treatment of atrial tachyarrhythmias comprises of rhythm and rate control, and prevention of thromboembolism. Patients with BTS often require both pacemaker and drug therapy. This article reviews the interactions of pacing and drug therapies in BTS. Drugs that alter cardiac electrophysiological properties may influence pacemaker indications, pacing mode selection, efficacy of pacing algorithms and pacing performance. Pacing by preventing drug-induced bradycardia increases the safety of pharmacotherapy and, thus, allows the intensification of those treatments. Pacing therapy and antiarrhythmic drugs used together as a hybrid therapy have a synergistic effect in the prevention of atrial tachyarrhythmias. Atrial-based pacing may reduce atrial tachyarrhythmia burden, allowing reduction of rhythm and rate control. Contemporary pacemakers' memory functions may help guide rhythm and rate control, as well as anticoagulation pharmacotherapy.
Collapse
Affiliation(s)
- Piotr Rucinski
- Department of Cardiology, Medical University of Lublin, 8 Jaczewskiego Street, 20-954 Lublin, Poland.
| | | | | |
Collapse
|
287
|
ACC/AHA/ESC: Guías de Práctica Clínica 2006 para el manejo de pacientes con fibrilación auricular. Versión resumida. Rev Esp Cardiol 2006. [DOI: 10.1157/13096583] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
288
|
Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006; 3:1445-52. [DOI: 10.1016/j.hrthm.2006.07.030] [Citation(s) in RCA: 220] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2006] [Accepted: 07/27/2006] [Indexed: 11/19/2022]
|
289
|
|
290
|
Budeus M, Wieneke H, Sack S, Erbel R, Perings C. Long-term outcome after cardioversion of atrial fibrillation: Prediction of recurrence with P wave signal averaged ECG and chemoreflexsensitivity. Int J Cardiol 2006; 112:308-15. [PMID: 16309759 DOI: 10.1016/j.ijcard.2005.09.025] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2005] [Revised: 09/19/2005] [Accepted: 09/21/2005] [Indexed: 11/18/2022]
Abstract
AIM The recurrence of atrial fibrillation after cardioversion was a general problem in medical practice. METHODS We wanted to test the hypothesis that the recurrence of atrial fibrillation could be predicted by measurements of P wave triggered P wave signal averaged ECG and chemoreflexsensitivity (CHRS) in 118 consecutive patients one day after successful electrical cardioversion. We measured the filtered P wave duration (FPD) and the root mean square voltage of the last 20 ms of the P wave (RMS 20) with P wave triggered P wave signal averaged ECG. The CHRS was calculated of a ratio between the difference of RR intervals in ECG and venous pO2 before and after 5-min oxygen inhalation. The pathologic CHRS was predefined as a CHRS below 3.0 ms/mm Hg. RESULTS A recurrence of atrial fibrillation was observed in 57 patients (48%) during a 9.3-month follow-up. The left atrial size (41.9+/-4.0 vs. 39.3+/-3.1 mm, P<0.0003) was larger, the FPD (139.6+/-16.0 vs. 118.2+/-14.1 ms, P<0.0001) was longer, the RMS 20 (2.57+/-0.77 vs. 3.90+/-0.99 muV, P<0.0001) and the CHRS (2.66+/-1.18 vs. 4.01+/-1.66 ms/mm Hg, P<0.0001) were lower in patients with recurrence of atrial fibrillation. A cut-off point was defined with FPD > or =126 ms and RMS 20 < or =3.1 muV and could predict atrial fibrillation with a specificity of 77%, a sensitivity of 72%, a positive value of 75%, a negative predictive value of 75% and an accuracy of 75%. Patients with FPD > or =126 ms and RMS 20 < or =3.1 muV had nearly a 7-fold increase risk for recurrence of atrial fibrillation. CONCLUSION The recurrence of atrial fibrillation after cardioversion could be detected by P wave signal averaged ECG and an analysis of CHRS. These methods seem to be appropriate to show a delayed atrial conduction and a neurovegetative imbalance which might be possible trigger mechanisms of reinitiating of atrial fibrillation.
Collapse
Affiliation(s)
- Marco Budeus
- Department of Cardiology, West-German Heart Centre, University of Duisburg-Essen, Germany.
| | | | | | | | | |
Collapse
|
291
|
Van Gelder IC, Hemels MEW. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 2006; 8:943-9. [PMID: 16973685 DOI: 10.1093/europace/eul107] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting young as well as elderly patients and presenting a major therapeutic challenge for clinical cardiologists. Recent research has elucidated the progressive nature of AF, including the structural and electrical remodelling that may become manifest if normal sinus rhythm is not restored, and the serious morbidities associated with long-term disease. The controversy over the merits of ventricular rate control vs. the restoration and maintenance of normal sinus rhythm in the treatment of AF has been explored in a number of large-scale, randomized clinical trials. The results of these trials suggest that whereas the two strategies may be equivalent for some patient populations, with both approaches requiring accompanying anticoagulation therapy, the restoration and maintenance of sinus rhythm provide important haemodynamic as well as subjective benefits not afforded by rate control. Although early intervention to limit the progression of this arrhythmia is hindered by the limitations of existing anti-arrhythmic therapies, it is nevertheless a critical goal.
Collapse
Affiliation(s)
- Isabelle C Van Gelder
- Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
| | | |
Collapse
|
292
|
Angerstein RL, Thronson F, Rasmussen MJ. Enhancing care for cardiac resynchronization therapy patients: device diagnostics and clinical application. J Cardiovasc Nurs 2006; 21:397-404. [PMID: 16966917 DOI: 10.1097/00005082-200609000-00010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Implantation of a cardiac resynchronization device in patients with heart failure does not attenuate the vigilant monitoring required by clinicians. Daily information about symptoms, quality of life, and weight are often part of routine care. Cardiac resynchronization devices also contain data on various heart failure parameters that can be obtained in or out of clinic. A number of cardiac resynchronization devices now have the ability to transmit such data to secure Internet sites, which can be accessed by clinicians. Incorporating these device data into daily practice can enhance current care. For instance, such data can confirm subjective patient reporting, help diagnose changes in the patient's condition, assist in deciding what changes to make in pharmacologic therapy, and assess the impact of device or pharmacologic therapy. Reviewing and utilizing device diagnostics may allow clinicians to intervene before a decompensation event and prevent a subsequent hospitalization. It is also likely that these device diagnostics can reduce the amount of time cardiovascular nurses spend on patient follow-up, thus enhancing efficiency in the clinical setting.
Collapse
|
293
|
Paraskevaidis IA, Vartela V, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D, Kremastinos DT. Tissue Doppler Imaging Analysis at Pre-Cardioversion Time Predicts Recurrent Atrial Fibrillation: A 12-Month Follow-Up Study. J Cardiovasc Electrophysiol 2006; 17:1005-10. [PMID: 16948745 DOI: 10.1111/j.1540-8167.2006.00566.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Tissue Doppler imaging (TDI) has been extensively used in several clinical settings. We aimed to investigate whether TDI can predict recurrent atrial fibrillation (AF). METHODS AND RESULTS Seventy-four consecutive patients (aged 62.6 +/- 11.7 years) with AF (>48 hours and <6 months of duration) who underwent successful external electrical direct current cardioversion and 20 healthy individuals were enrolled. Conventional echocardiography and TDI were prospectively performed before cardioversion. Based on a cutoff point of 5.43 cm/sec for the negative systolic wave velocity (NSWV), derived by the normal controls (mean + 2 SD), patients were divided into Group I (36 patients) with a NSWV >5.43 cm/sec and Group II (38 patients) with NSWV <or=5.43 cm/sec. In Group I, 27.8% of patients were in sinus rhythm at 6 months, but had episodes of asymptomatic paroxysmal AF lasting >48 hours; all patients were in AF at 12 months. In Group II, all patients were in sinus rhythm at 12 months. However, those patients presenting with a NSWV less but near to 5 cm/sec had frequent episodes of asymptomatic paroxysmal AF lasting for <48 hours. CONCLUSION One year after successful direct current cardioversion, TDI analysis at pre-cardioversion time may be a useful marker to identify a subgroup of patients with increased risk for AF recurrence.
Collapse
|
294
|
Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, Israel CW, Lau CP, Morillo C, Connolly SJ. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J 2006; 152:442-7. [PMID: 16923410 DOI: 10.1016/j.ahj.2006.02.016] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2005] [Accepted: 02/05/2006] [Indexed: 02/03/2023]
Abstract
Asymptomatic atrial fibrillation (AF) is common and may have the same prognostic implications as symptomatic AF. Among patients receiving dual-chamber pacemakers, it is now possible to quantify asymptomatic AF accurately. Most of these episodes are of short duration, often lasting only seconds to minutes and are called atrial high-rate episodes (AHRE) to distinguish them from the longer episodes of overt AF. To understand properly the clinical importance of asymptomatic AF, a large study of pacemaker patients without clinically overt AF is required. ASSERT is a multicenter, cohort follow-up, and single-blinded randomized trial in elderly hypertensive patients with a pacemaker recently implanted for sinus or atrioventricular node disease. The goals of this trial are to evaluate whether the detection of AHRE with pacemaker telemetry predicts an increased risk of stroke and other vascular events and to evaluate if atrial overdrive pacing reduces symptomatic AF. ASSERT is evaluating the hypothesis that among pacemaker patients without a previous history of AF, detection of AHRE predicts an increased risk of stroke and systemic embolism. The second hypothesis to be tested is that overdrive atrial pacing will reduce the risk of symptomatic AF in pacemaker patients without a previous history of AF. Finally, a 400-patient substudy will use the noninvasive testing capabilities of the patients' pacemaker to evaluate changes in atrial electrophysiology over 2 years. This substudy will determine if atrial electrical remodeling is detectable in pacemaker patients and if it is associated with the development of AF.
Collapse
Affiliation(s)
- Stefan H Hohnloser
- Division of Electrophysiology, Department of Cardiology, J.W. Goethe-University, Frankfurt, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
295
|
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-354. [PMID: 16908781 DOI: 10.1161/circulationaha.106.177292] [Citation(s) in RCA: 1381] [Impact Index Per Article: 76.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
296
|
|
297
|
|
298
|
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. J Am Coll Cardiol 2006; 48:854-906. [PMID: 16904574 DOI: 10.1016/j.jacc.2006.07.009] [Citation(s) in RCA: 717] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
299
|
|
300
|
Colonna P, Sorino M, de Luca L, Bovenzi F, de Luca I. Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM study. J Cardiovasc Med (Hagerstown) 2006; 7:505-13. [PMID: 16801812 DOI: 10.2459/01.jcm.0000234769.50583.f1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
In the last few decades several clinical studies evaluated the efficacy and safety of different strategies for antithrombotic prophylaxis to prevent thromboembolic events in patients with atrial fibrillation (AF). Nowadays, a frequently debated point is related to the high embolic risk deriving from the asymptomatic and symptomatic AF recurrence after cardioversion or in paroxysmal AF, especially in patients with a large number of prolonged episodes of AF. In fact, after the recent AFFIRM and RACE trials, patients after successful cardioversion at risk for thromboembolism could also need lifelong anticoagulation. Considering this, should we anticoagulate all patients with clinical risk factors for thromboembolism with a single episode of AF, without considering the hemorrhagic risk? Based on recent trials, it is reasonable to hypothesize that long AF recurrences (> 48 h), both symptomatic and asymptomatic, are present mostly (if not exclusively) in patients with structural left atrial appendage (LAA) dysfunction and remodeling. Conversely, AF recurrences in patients without LAA dysfunction and remodeling, could be too short to allow thrombi formation in the LAA, and the anticoagulation could also be avoided. Once other clinical and echocardiographic determinants of stroke have been excluded, the LAA velocity could select patients with a normal appendage function at low embolic risk who could benefit from anti-aggregation and patients with irreversible appendage dysfunction, at high embolic risk, who need lifelong anticoagulation.
Collapse
|